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Abstract. – OBJECTIVE: Methylphenidate is
commonly used in the treatment of Attention
Deficit Hyperactivity Disorder and narcolepsy.
Methylphenidate is administered as a racemic
mixture of the d- and l- threo enantiomers; how-
ever, the d-enantiomer is primarily responsible
for the pharmacologic activity. Previous studies
of the behavioral effects of methylphenidate
have highlighted sex differences in the respon-
siveness to the drug, namely an increased sen-
sitivity of females to its stimulatory effects.
These differences may be due to differences in
the uptake, distribution, and elimination of
methylphenidate from male and female brains.
Therefore, we compared the pharmacokinetics
of d- and l- threo methylphenidate in the brains
of male and female rats.
MATERIALS AND METHODS: Adult male and
female Sprague-Dawley rats were injected with 5
mg/kg d, l- threo methylphenidate, and whole
brains were collected at various time points fol-
lowing injection. We measured methylphenidate
concentrations utilizing chiral high pressure liquid
chromatography followed by mass spectrometry.
RESULTS: Females exhibited consistently
higher brain concentrations of both d- and l-
methylphenidate and a slower clearance of
methylphenidate from brain as compared to
males, particularly with the active d-enantiomer.
CONCLUSIONS: The increased sensitivity of
females to methylphenidate may be partially ex-
plained by an increase in total brain exposure
to the drug.
Key Words:
Methylphenidate, Brain, Chiral separation, Sex dif-
ferences, Liquid chromatography-mass spectrometry.
Introduction
Methylphenidate (MPH) is commonly used in
children and adolescents for the treatment of At-
tention Deficit Hyperactivity Disorder (ADHD)
and narcolepsy. According to current estimates,
5.9-7.1% of children and 5.0% of adults are affect-
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ed by ADHD, and MPH is the first line treatment,
accounting for a majority of the prescriptions writ-
ten for the disorder1-3. Additionally, increases in
off-label use and diversion of MPH have been re-
ported4-6. MPH works in the brain by blockade of
both the dopamine transporter (DAT) and the nor-
epinephrine transporter (NET), which leads to an
increase in both dopamine and norepinephrine in
the synaptic cleft. Given the fact that MPH in-
creases extracellular dopamine, it has the potential
for abuse7. In fact, it is more potent at blocking the
DAT than cocaine8. However, its limited abuse in
the context of clinical use appears to be due to
pharmacokinetics, namely its slow, steady uptake
in the brain when taken orally9.
Methylphenidate has two chiral centers; how-
ever, only the threo enantiomers are used in ther-
apy, as they are more pharmacologically potent10.
Although the drug is administered as a racemic
mixture of the d- and l- threo enantiomers, the d-
MPH enantiomer is thought to be primarily, if
not entirely, responsible for the pharmacologic
activity11-14. Interestingly, MPH is also subject to
stereoselective metabolism. MPH is subject to
hydrolysis of the methyl ester linkage via the en-
zyme carboxylesterase 1 (CES1) to the pharma-
cologically inactive d- or l- ritalinic acid11,15. It is
well-recognized the CES1 is considerably more
efficient in the de-esterfication of l-MPH relative
to d-MPH, resulting in a significantly higher
bioavailability of the d- enantiomer14,15.
Most of the previous studies analyzing the ef-
fects of MPH on the brain and behavior have uti-
lized males as subjects. This trend is likely due to
the recognized higher prevalence of ADHD in
males versus females and the biological com-
plexity of females due to their reproductive cy-
cling16. However, both human and animal studies
have indicated some important gender differ-
ences in ADHD manifestations, as well as re-
sponsiveness to psychostimulants17-20. For exam-
2015; 19: 2514-2519
5 min, 10 min, 30 min, 60 min, and 120 min, and
an n of 6 to 7 for each sex at each time point was
used to ensure appropriate statistical power.
Whole brains were flash frozen in liquid nitrogen
and stored at –70°C for later use. All animals
were housed in an Association for the Assess-
ment and Accreditation of Laboratory Animal
Care (AALAC) accredited facility with food and
water provided ad libitum. All procedures were
carried out according to NIH guidelines and were
approved by the East Tennessee State University
Committee on Animal Care.
Tissue Collection and Sample Preparation
Solid phase extraction was utilized to extract
MPH from brain tissue according to our previ-
ously validated method27; this method allows for
extraction recovery of 72-75% for both d- and l-
threo methylphenidate and both low (10 ng/mL)
and high (100 ng/mL) calibration concentrations.
Liquid Chromatography-Mass Spectrometry
Methylphenidate concentrations were mea-
sured using liquid chromatography-mass spec-
trometry (LC-MS). Since MPH is administered
as a racemic mixture of the d- and l- threo forms,
these enantiomers were separated and measured
individually as described previously27. This
method allowed for a lower limit of detection
(LLOD) of 0.5 ng/mL and a lower limit of quan-
tification (LLOQ) of 7.5 ng/mL, with desirable
intra- and inter-day precision and accuracy (%
RSD and % error were < 15% for every calibra-
tion point).
Statistical Analysis
All data were subjected to a noncompartmen-
tal analysis utilizing the Phoenix 64/WinNonLin
software. Parameters of interest included the area
under the curve (AUC), the maximal concentra-
tion (Cmax), the time of maximal concentration
(Tmax), the clearance from the brain (Cl),and the
elimination half-life (T1/2) from the brain. If stan-
dard errors were reported, the results of these
analyses were compared using an ANOVA fol-
lowed by Newman-Keuls Multiple Comparison
Tests. Data were considered to be statistically
significantly different when p < 0.05.
Results
The d- and l- threo enantiomers of MPH were
measured using LC-MS. Interestingly, females
ple, Patrick and colleagues reported that females
described a significantly greater stimulant effect
of MPH than males when asked in a self-report
analysis21. Interestingly, a number of animal
studies also indicate the presence of sex differ-
ences in response to MPH. In one study, adult fe-
male rats demonstrated increased conditioned hy-
peractivity to both moderate and high doses of
MPH as compared to adult male rats22. Addition-
ally, in two recent studies, females demonstrated
behavioral sensitization (or increased locomotor
responses to subsequent exposure) to MPH
whereas males did not23,24.
In sum, several studies seem to indicate an in-
creased responsiveness of females to MPH. One
of these studies was conducted in collaboration
with our laboratory, and it revealed that female
rats demonstrated more robust sensitization to
MPH and increased locomotor activation com-
pared to males23. These sex differences could be
due to pharmacodynamic and/or pharmacokinetic
factors. Since drug effect is directly related to
brain concentrations, here, we investigate MPH
pharmacokinetics in male and female brains.
Specifically, we compare the uptake, distribution,
and elimination of d- and l- threo MPH in the
brains of male and female rats.
Materials and Methods
Animals
Fifty day old rats were chosen for this study in
order to follow up on previous behavioral work
conducted in collaboration with our laboratory23.
In that particular study, rats received injections of
MPH or saline every other day from P33 through
P50; locomotor activity and behavioral sensitiza-
tion was analyzed throughout this time period,
and in females, the most robust effect occurred
after day 50 with a dose of 5 mg/kg MPH. As
such, we aimed to investigate the pharmacokinet-
ics of MPH in animals at this developmental age
(P50) using an identical dose. Furthermore, the 5
mg/kg dose has been utilized in other studies to
mimic an “abusive dose” of MPH, and intraperi-
toneal (IP) administration is believed to mimic
the absorption seen in snorting23,25,26. As such, 50
day old Sprague-Dawley rats (150-200 g) were
injected intraperitoneally with 5 mg/kg d, l- threo
methylphenidate HCl (Sigma Aldrich, St. Louis,
MO, USA) prepared in sterile physiological
saline. Animals were sacrificed via decapitation
at the following time points post injection: 1 min,
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Figure 1. Pharmacokinetics of A, l- and B, d- methylphenidate
(MPH) following intraperitoneal injection of 5 mg/kg MPH in
females (solid line) and males (dotted line). Data are expressed
as the mean ± SEM, n = 6-7.
Figure 2. A, Maximal concentrations of d- and l-MPH (Cmax)
following injection of 5 mg/kg MPH. No statistically significant
differences were achieved. B, Total brain d- and l- MPH expo-
sure as calculated by the area under the curve (AUC) in males
versus females. *p < 0.05 versus the AUC of d-MPH in males (n
= 6); One way ANOVA followed by Newman-Kuels multiple
comparisons test.
appeared to exhibit consistently higher brain con-
centrations of both d- and l- MPH (Figure 1). Ad-
ditionally, the d-enantiomer appeared to be main-
tained in the brain at higher concentrations as
compared to the l-enantiomer in both females
and males (Figure 1). Subsequently, the pharma-
cokinetic data were analyzed via noncompart-
mental analysis with Phoenix 64/WinNonLin
software. Although the maximal concentrations
(Cmax) of d- and l- MPH were not significantly
different in males as compared to females (Fig-
ure 2A), the total brain exposure to the drug, as
indicated by the area under the curve (AUC), was
significantly higher in females versus males (Fig-
ure 2B).
Based on the pharmacokinetic model created
by the noncompartmental analysis, several other
parameters were calculated including the time of
maximal concentration (Tmax), the half-life of
MPH in the brain (T1/2), and the clearance of
MPH from the brain (Cl). (Table I). Since the da-
ta are theoretical, standard errors could not be
calculated. Interestingly, the T1/2 for either enan-
tiomer did not appear to be substantially different
between the sexes. Additionally, the Tmax for both
d- and l- in males and females was 10 min. How-
ever, there did appear to be some sex differences
that should be noted; females exhibited a slower
Cl of MPH as compared to males, particularly
with the d-enantiomer (88.45 g/min versus
2517
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144.22 g/min). Finally, when comparing the
enantiomers, the T1/2 appeared to be slightly
longer and the Cl slightly less for d-MPH as
compared to l-MPH.
Discussion
In this study, we examined the brain pharmaco-
kinetics of d- and l- threo MPH in male and fe-
male rats following intraperitoneal injection of 5
mg/kg MPH. Interestingly, we discovered the fe-
males had consistently higher brain concentrations
of both d- and l- MPH than males, resulting in a
significantly higher overall brain exposure to
MPH (as represented by the AUC). This was ac-
companied by a notable decrease in the rate of
clearance of MPH from the brain for both enan-
tiomers, but most profoundly with the pharmaco-
logically active d-enantiomer. The reason for the
sex differences in the pharmacokinetics of MPH is
currently unclear. To date, there is little known re-
garding the extent to which transporters contribute
to movement of MPH across the blood-brain barri-
er; however, one study indicates that a carrier-me-
diated process is at least partially responsible28.
This carrier is saturable and is also responsible for
the uptake of amphetamine and β-phenethy-
lamine. In addition, one study indicated that d-
MPH is a weak substrate of P-glycoprotein29.
Given the fact that transporters are at least partial-
ly responsible for access of methylphenidate to
the brain, sex differences in the levels of these
transport proteins may contribute to the differ-
ences observed in this study. Another possible ex-
planation for the increased levels of MPH in fe-
males as compared to males would be sex differ-
ences in the metabolism of methylphenidate. As
noted earlier, methylphenidate is subjected to hy-
drolysis via the CES1 enzyme; if males have
higher CES1 activity than females, this would re-
sult in lower bioavailability of MPH and thus
lower brain concentrations. Regardless, these re-
sults may at least partially explain the previous
findings that females are more sensitive to the
psychostimulant effects of MPH. Specifically, in
a study completed in conjunction with our labo-
ratory, females demonstrated robust locomotor
sensitization in response to 5 mg/kg MPH,
whereas males did not.
In this study, we also quantified the levels of
d- and l- threo MPH separately. Of note, the
AUC for d-MPH was also significantly greater
than the AUC for l-MPH in both males and fe-
males, thereby indicating greater exposure to the
more active enantiomer. This is likely due to the
enhanced bioavailability of this enantiomer due
to preferential hydrolysis of l- threo MPH by
CES1, which in rodents is active in both the liver
and the plasma14,15. Brain concentrations found in
this study (725 ± 87.0 at 10 min and 552.7 ± 60.2
at 30 min, pooled d- and l-MPH, male and fe-
male data) utilizing LC-MS were similar to pre-
vious reports employing other methodologies;
Levant and colleagues used an ELISA-based as-
say to find that adult rats at postnatal days 42 and
70 had brain concentrations of 985 ± 44 ng/g and
1006 ± 32 ng/g, respectively, 20 min following
subcutaneous administration of 5 mg/kg MPH30.
In that particular study, the enantiomers were not
quantified separately, and multiple time points
were not examined. A few other studies have ex-
amined brain concentrations of MPH in rats, yet
the doses and/or methods of administration used
in these studies were vastly different, making di-
rect comparisons difficult31-35.
Table I. Theoretical pharmacokinetic parameters as calculated through pharmacokinetic modeling. Values for half-life (T ½),
time of maximal concentration (T max), and clearance (Cl) from the brain are presented.
Values for half-life (T½), time of maximal concentration (Tmax), and clearance (Cl) from the brain are presented.
Conclusions
In summary, we have found significant sex dif-
ferences in the pharmacokinetics of MPH; name-
ly, females have a higher overall brain exposure
to MPH as compared to males, especially with
the d-enantiomer. Additionally, the elimination of
MPH from the brain as represented by the clear-
ance appears to be substantially slower in fe-
males. Future studies are needed to determine the
reason for the sex-related differences, but they
could be related to variance in metabolism be-
tween the sexes or differences in the rate of trans-
port of methylphenidate across the blood brain
barrier. Nonetheless, these data may explain
many of the previously documented sex differ-
ences in the responses to this psychostimulant in-
dicating an increased sensitivity of females to the
drug.
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